liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation
Varde Heart Centre, Denmark.
Varde Heart Centre, Denmark.
Linköping University, Department of Medical and Health Sciences. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart and Medicine Center, Department of Cardiology in Linköping. Varde Heart Centre, Denmark.ORCID iD: 0000-0003-3059-4404
2016 (English)In: Danish Medical Journal, E-ISSN 2245-1919, Vol. 63, no 2, A5186- p.Article in journal (Refereed) PublishedText
Abstract [en]

INTRODUCTION: Limited data are available regarding safety of catheter ablation of atrial fibrillation (AF) in patients using novel oral anticoagulants (NOAC) before and after pulmonary vein isolation. We aimed to assess the safety of a simple anticoagulation protocol in consecutive patients -presenting for catheter ablation of AF. METHODS: From November 2011 to December 2014, we prospectively included 234 patients referred for catheter ablation of AF who had already received NOAC treatment. NOAC was continued for a minimum of three months after ablation. We assessed procedure-related bleeding or thromboembolic complications, bleeding or thromboembolic complications during a three-month follow-up period and patient-reported adherence to NOAC therapy. The study has not received financial support from external resources. The study was registered with ClinTrials.gov as NCT02569255. RESULTS: A total of 171 patients were treated with dabigatran (94% 150 mg twice daily), 38 with rivaroxaban (100% 20 mg daily) and 25 with apixaban (100% 5 mg twice daily). NOACs were interrupted for 24 hours before and re-administered two hours after the ablation procedure, without bridging with low molecular weight heparin (LMWH). No periprocedural thromboembolic complications and no bleeding complications were registered except for one pericardial effusion which was percutaneously drained without further complications. No thromboembolic or bleeding complications during follow-up were registered. All patients continued the same NOAC during follow-up as before ablation. CONCLUSIONS: Anticoagulation with NOAC with a short period of periprocedural interruption without bridging with LMWH seems safe and well-tolerated.

Place, publisher, year, edition, pages
Copenhagen, Denmark: Danish Medical Association , 2016. Vol. 63, no 2, A5186- p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-125816ISI: 000369635000008PubMedID: 26836793OAI: oai:DiVA.org:liu-125816DiVA: diva2:910255
Available from: 2016-03-08 Created: 2016-03-04 Last updated: 2016-04-05Bibliographically approved

Open Access in DiVA

No full text

Other links

PubMedLink to publication

Search in DiVA

By author/editor
Walfridsson, Håkan
By organisation
Department of Medical and Health SciencesFaculty of Medicine and Health SciencesDepartment of Cardiology in Linköping
In the same journal
Danish Medical Journal
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 338 hits
ReferencesLink to record
Permanent link

Direct link